Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Rituximab or Rituximab + Chemotherapy in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

NCT02953509 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT02953509
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02953509 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Rituximab or Rituximab + Chemotherapy in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Lead sponsor
Gilead Sciences
Phase
Phase 1/2
Overall status
Terminated
Start date
November 21, 2016
Completion date
March 25, 2024
Enrollment
178 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

non hodgkin lymphoma